Wouter W. de Herder

Research interests

Publications

• [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

  The Lancet · 2024 · 10.1016/s0140-6736(24)00701-3

• Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms

  Endocrine Pathology · 2022 · https://doi.org/10.1007/s12022-022-09708-2

• Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

  Clinical Cancer Research · 2017 · https://doi.org/10.1158/1078-0432.ccr-16-2743

• ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms

  Neuroendocrinology · 2016 · 10.1159/000443166

• ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms

  Neuroendocrinology · 2016 · 10.1159/000443168

• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

  Annals of Oncology · 2015 · 10.1093/annonc/mdv041

• Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature

  Endocrine Related Cancer · 2013 · 10.1530/erc-13-0125

• TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study

  JNCI Journal of the National Cancer Institute · 2012 · https://doi.org/10.1093/jnci/djs208

• ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

  Neuroendocrinology · 2012 · https://doi.org/10.1159/000335591

• NANETS Treatment Guidelines

  Pancreas · 2010 · 10.1097/mpa.0b013e3181ebb168

• Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study

  The Journal of Clinical Endocrinology & Metabolism · 2010 · https://doi.org/10.1210/jc.2009-2556

• Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

  Endocrine Related Cancer · 2009 · https://doi.org/10.1677/erc-09-0078

• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs

  Neuroendocrinology · 2009 · 10.1159/000225951

• An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis

  The Lancet Oncology · 2009 · https://doi.org/10.1016/s1470-2045(09)70164-0

• Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.15.2553

• Gastroenteropancreatic neuroendocrine tumours

  The Lancet Oncology · 2008 · https://doi.org/10.1016/s1470-2045(07)70410-2

• Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families

  The Journal of Clinical Endocrinology & Metabolism · 2007 · 10.1210/jc.2006-2513

• Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma

  Neuroendocrinology · 2006 · 10.1159/000098010

• TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system

  Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2006 · https://doi.org/10.1007/s00428-006-0250-1

• Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.08.066

• Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours

  Neuroendocrinology · 2004 · 10.1159/000085237

• Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

  European Journal of Nuclear Medicine and Molecular Imaging · 2003 · https://doi.org/10.1007/s00259-002-1050-8

• Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

  Seminars in Nuclear Medicine · 2002 · 10.1053/snuc/2002.31025

• Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the α-Subunit of Glycoprotein Hormones

  The Journal of Clinical Endocrinology & Metabolism · 1997 · 10.1210/jcem.82.8.4145

• Octreotide

  New England Journal of Medicine · 1996 · https://doi.org/10.1056/nejm199601253340408

Current projects

No projects listed.